Navigation Links
CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges

KING OF PRUSSIA, Pa., Dec. 2, 2011 /PRNewswire/ -- CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders. CSL Behring has awarded more than $600,000 in grants to patient organizations since the LEAD program was established in 2008.


The grant will be used to create the A-PLUS State Exchange Project, which will educate state advocates on the development of state insurance exchanges, including federally defined essential health benefits that establish the minimum requirements of exchanges.  The project will also help state advocates educate patients about implementation of the exchanges and how they can participate to ensure that access to specialized care and treatments will be maintained in the plans offered through the state insurance exchanges.

A-PLUS partners include:

  • Alpha-1 Association
  • Alpha-1 Foundation
  • Committee of Ten Thousand
  • GBS/CIDP Foundation International
  • Hemophilia Federation of America
  • Immune Deficiency Foundation
  • Jeffrey Modell Foundation
  • National Hemophilia Foundation
  • Patient Services Incorporated
  • Platelet Disorder Support Association

Larry LaMotte, Director of Government Affairs for the Immune Deficiency Foundation said, "This project will allow each organization's volunteers to be educated and trained to advocate effectively on behalf of their patient population and to make sure the development of state health exchanges provides protections for all patients with rare and chronic diseases. 

"The second benefit will be the development of trained patients to educate and assist other patients to be able to choose wisely the best insurance plans when the health care reform law goes into effect in January, 2014. The third benefit is that this project will allow the opportunity for plasma users of the different patient communities to work together as advocates in their respective states to affect the public policies that may affect them."

According to Michelle Rice, Regional Director for Chapter Services at the National Hemophilia Foundation, many of those affected by bleeding disorders have already been positively impacted by the new patient protections provided in the Affordable Care Act. "The expansion of state Medicaid programs and the creation of state health insurance exchanges in 2014 have the potential to offer consumers something many have never experienced – choices for health care coverage," Rice said.

CSL Behring's Senior Vice President of Public Affairs, Dennis Jackman added, "We are looking for opportunities to collaborate with patient organizations to advance advocacy initiatives. Providing a LEAD grant to A-PLUS for the state exchange project will positively impact patients represented by all the coalition members. The state insurance exchanges are a crucially important area where education and advocacy are needed, and we are very pleased to support this effort." 

LEAD grants are awarded semi-annually. CSL Behring considers grant proposals that relate to bleeding and platelet disorders, immune deficiencies, pulmonary disease and critical care. The submission deadline for the next round of grants is April 30, 2012. Applications, specific criteria for applying and more information about the LEAD program are available at

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For information:


Chris Florentz, Manager Corporate Communications



Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference
2. CSL Behring Marks World Hemophilia Day by Announcing the Winners of the CSL Behring - Prof. Heimburger Award 2011
3. CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington
4. ProFibrix and CSL Behring Enter Into Fibrinogen and Thrombin Supply Agreement
5. CSL Behrings Innovative HeliTrax(SM) System Helps Physicians Manage Hemophilia A Patients
6. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
7. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual StevieĀ® Awards for Women in Business
8. BioCrossroads Awards Indiana Life Sciences Leaders
9. 1 Award Winner and 9 Prize Winners in the EFQM Business Excellence Awards
10. Cellular Dynamics Internationals (CDI) Human Induced Pluripotent Stem Cell (iPSC) Technology Named the Gold Winner in The Wall Street Journal 2011 Technology Innovation Awards
11. Parent Project Muscular Dystrophy Awards End Duchenne Grant to University of Pennsylvanias Dr. Tejvir S. Khurana
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):